- Celsion is required to make an upfront payment of $3.4M, and to fund that closes on its 2nd $5M tranche under its $20M Loan and Security Agreement with Hercules Technology Growth Capital (HTGC). Under terms of that Agreement made last November, Celsion obtained consent from Hercules to move forward with the purchase.
- The funding is variable-rate, and Hercules also has a warrant (expiring in 2018) to buy nearly 200K shares of Celsion at $3.59 each.
- Source: Press Release
- Previously: Celsion buys cancer therapeutics firm
From other sites
at Nasdaq.com (Mar 9, 2015)
at CNBC.com (Oct 14, 2014)
at CNBC.com (Aug 14, 2014)
at CNBC.com (Jun 29, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs